Lobular breast carcinoma in situ – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:28:46 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lobular breast carcinoma in situ – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparison of Low-Dose Exemestane versus Low-Dose Tamoxifen for Breast Cancer Prevention in Postmenopausal Women at High Risk https://clinicaltrials.eu/trial/comparison-of-low-dose-exemestane-versus-low-dose-tamoxifen-for-breast-cancer-prevention-in-postmenopausal-women-at-high-risk/ Wed, 29 Apr 2026 15:06:15 +0000 https://clinicaltrials.eu/trial/comparison-of-low-dose-exemestane-versus-low-dose-tamoxifen-for-breast-cancer-prevention-in-postmenopausal-women-at-high-risk/ This clinical trial is studying breast cancer prevention in postmenopausal women who are at high risk for developing breast cancer. The study compares two medications at low doses: exemestane (called “babyexe”) versus tamoxifen (called “babytam”). Exemestane and tamoxifen are both medications that can affect hormone activity in the body. Postmenopausal refers to women who have not had menstrual periods for at least 12 months.

The purpose of this study is to compare how these two low-dose medications affect quality of life in high-risk women. High-risk factors may include previous abnormal breast findings, family history of breast cancer, certain genetic variations, or previous radiation to the chest area before age 30. The trial is described as “randomized” and “double blind,” which means participants will be assigned by chance to receive either babyexe or babytam, and neither the participants nor the researchers will know which medication each person is receiving during the study.

Participants in this study will take their assigned medication and be evaluated at various points, including at 6 months and 12 months after starting treatment. The researchers will assess various aspects of quality of life, including physical symptoms, hot flashes (vasomotor symptoms), sexual health, and psychological well-being. They will also monitor for any side effects and measure certain hormone levels and bone markers in the body.

]]>